This site is intended for healthcare professionals
Latest industry news
  • Home
  • /
  • News
  • /
  • 2016
  • /
  • 08
  • /
  • Mallinckrodt sells its nuclear imaging business to...
Industry news

Mallinckrodt sells its nuclear imaging business to IBA Molecular for $690 million.

Read time: 1 mins
Last updated:26th Aug 2016
Published:26th Aug 2016
Source: Pharmawand
Mallinckrodt plc, a leading specialty pharmaceutical company, announced that it has entered into a definitive agreement under which it will sell its Nuclear Imaging business to IBA Molecular, for approximately $690 million before tax impacts, including up-front and contingent consideration and the assumption of long-term obligations. Mallinckrodt's Nuclear Imaging business includes a portfolio of diagnostic imaging products. Though approved for use and sold for nuclear medicine procedures in many countries, approximately two-thirds of current annual revenues from Mallinckrodt's Nuclear Imaging business originate in the U.S. The business is a prominent global producer of the key medical isotope molybdenum-99, from which technetium-99m (Tc-99m) is derived. Tc-99m is used in roughly 80%1 of all nuclear medicine procedures worldwide, and Mallinckrodt is a significant U.S. and global supplier of this radioisotope.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.